ArticleLung India : official organ of Indian Chest Society2025
Sensitivity and specificity of Gene Xpert Ultra in extrapulmonary tuberculosis (EPTB).
Article in Lung India : official organ of Indian Chest Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic utility of Xpert MTB/RIF ultra in clinically suspected tuberculous lymphadenitis in low-burden settings: a single center experience from Saudi Arabia.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- A three-phase epidemiological fluctuation framework of extrapulmonary tuberculosis in Fuyang, China: a retrospective study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGene Xpert sensitivity is low in paucibacillary conditions like extrapulmonary tuberculosis (EPTB); to overcome that, Gene Xpert Ultra was introduced. This study aims to assess Gene Xpert Ultra's diagnostic accuracy in EPTB.
methodsThis prospective observational study was conducted at Apollo Hospital, Greams Road, Chennai, Tamil Nadu, India, from May 2022 to April 2023. A total of 200 patients, 39 (19.5%) abdominal, 61 (30.5%) musculoskeletal, one (0.5%) bone marrow, 50 (25%) lymph nodes, 11 (5.5%) CNS, two (1%) upper airway, one (0.5%) cardiovascular, and 35 (17.5%) pleural cases were enrolled. Samples were analyzed for Gene Xpert Ultra, MGIT culture, cytology, and histopathology wherever feasible with tuberculosis. Tissue sampling was performed rather than bodily fluid in all cases except in CNS and abscess, where CSF and pus were analyzed, respectively. Gene Xpert Ultra was then compared with MGIT culture and Composite reference standard (CRS).
resultsThe pooled sensitivity and specificity of Gene Xpert Ultra were 96.18% and 18.84% against MGIT and 94.30% and 100% against CRS. The lowest sensitivity (90%) was in CSF, and the highest (100%) was in pleura against CRS.
conclusionGene Xpert Ultra has high sensitivity and specificity in tissue samples in various system involvements. This study recommends employing Gene Xpert Ultra in EPTB and further encourages tissue sample testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.